David P. Al-Adra, MD, PhD, FACS
- Division of Transplantation
600 Highland Avenue
Madison WI 53792-7375
- MD, University of Alberta, 2007
- PhD, Clinical Investigator Program in the Department of Surgery, University of Alberta, 2012
- Residency, General Surgery, University of Alberta, 2015
- Abdominal Organ Transplant Fellowship, University of Toronto, 2017
Dr. Al-Adra is certified by the American Board of Surgery (ABS), the American Society of Transplant Surgeons (ASTS), the Royal College of Surgeons of Canada, and the Americas Hepato-Pancreato-Biliary Association (AHPBA). He specializes in liver, kidney, pancreas and pediatric transplantation, live donor liver transplantation (LDLT), and hepatobiliary surgery.
David P. Al-Adra provides a wide range of services including Kidney Transplant, Laparoscopic Donor Nephrectomy, Liver Resection, Liver Transplant, Pancreas Transplant, Pediatric Liver Transplant, Wedge Resection of the Liver.
Dr. Al-Adra aims to investigate the mechanisms of immunological tolerance and attempt to induce tolerance to transplanted organs through organ pre-treatment and recipient preconditioning. The overall goal is to decrease immunity and promote tolerance towards solid organ transplants in order to decrease the need for immunosuppressive therapy. Specifically, this would involve investigating the cell surface expression of co-inhibitory and co-stimulatory structures of hepatocytes using flow cytometry. Modification of the expression of these surface molecules will then be done to promote co-inhibition and enhance immunological regulation. Ex-vivo perfusion technologies will allow investigation of different reagents and delivery systems used for whole organ modification. Further investigation would include evaluating the effect on the vascular microenvironment and local immune infiltration using cellular imaging.
Pancreas Transplants from small donors: are the outcomes acceptable?
Al-Qaoud TM, Odorico JS, Al-Adra DP, Kaufman DB, Sollinger HW, Leverson G, Welch B, Redfield RR
Transpl. Int. 2020 Aug 04;
[PubMed ID: 32749728]
Microsteatosis in Livers from Donation after Circulatory Death (DCD) Donors Is Associated with Inferior Outcomes Following Liver Transplantation.
Bath NM, Leverson G, Al-Adra D, D'Alessandro A, Mezrich J, Foley DP
Liver Transpl. 2020 May 26;
[PubMed ID: 32453905]
Outcomes following bioprosthetic valve replacement in prior non-cardiac transplant recipients.
Bozso SJ, Kang JJH, Al-Adra D, Hong Y, Moon MC, Freed DH, Nagendran J, Nagendran J
Clin Transplant 2019 11; 33(11): e13720
[PubMed ID: 31556148]
Donor kidney volume measured by computed tomography is a strong predictor of recipient eGFR in living donor kidney transplantation.
Al-Adra DP, Lambadaris M, Barbas A, Li Y, Selzner M, Singh SK, Famure O, Kim SJ, Ghanekar A
World J Urol 2019 Sep; 37(9): 1965-1972
[PubMed ID: 30523400]
Live donor liver transplantation with older donors: Increased long-term graft loss due to HCV recurrence.
Goldaracena N, Barbas AS, Galante A, Sapisochin G, Al-Adra D, Selzner N, Galvin Z, Cattral MS, Greig PD, Lilly L, Bhat M, McGilvray ID, Ghanekar A, Levy G, Grant DR, Selzner M
Clin Transplant 2018 08; 32(8): e13304
[PubMed ID: 29947154]